GE Healthcare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As

GE HealthCare (GEHC) is positioned for revenue growth driven by a strong backlog, China stimulus deployment, and product innovations like Flyrcado, further bolstered by potential M&A activity given its healthy balance sheet. While tariff-related headwinds are expected to impact margins in the near term, management is implementing mitigation strategies, with margins anticipated to bottom in Q3 and improve sequentially thereafter. Trading at a discount to peers, GEHC is rated a buy based on long-term growth prospects and potential for margin recovery, despite risks associated with tariffs and M&A execution.

Analysis

GE HealthCare Technologies (GEHC) demonstrates a robust top-line outlook, underpinned by a 10% year-over-year increase in orders, a 1.09x book-to-bill ratio, and a substantial $20.6 billion backlog, which provides strong revenue visibility. Q1 revenue grew 2.7% Y/Y (4.1% organic), led by the Pharmaceutical Diagnostics (PDx) segment's 7.8% organic growth and the Imaging segment's 5.0% organic growth. While demand in the US and Europe remains resilient, a recovery in China is anticipated in late 2025 as stimulus funding is deployed. The near-term challenge is margin compression, stemming primarily from a potential $475 million impact from tariffs, which is expected to cause margins to bottom in Q3. However, management is actively mitigating this through price increases, cost controls, and shifting to local-for-local manufacturing. The company's adjusted EBIT margin rose 30 bps to 15% in Q1, despite a 440 bps drop in the Patient Care Solutions segment margin. With a healthy balance sheet (1.74x net leverage), GEHC is also pursuing inorganic growth, as seen with the Nikon Med-Physics acquisition. Trading at 17.7x forward earnings, a discount to its peers, the stock appears to have priced in these near-term margin headwinds.

Key Decisions for Investors

• Given the strong order backlog and valuation discount to peers, investors may consider the current share price an attractive entry point, viewing the well-publicized tariff headwinds as a temporary and priced-in issue.
• Investors should closely monitor the Q3 earnings report for confirmation that margins have troughed and that mitigation strategies are gaining traction, as this will be a key catalyst for a potential re-rating.
• Pay attention to any signs of an accelerated recovery in China's hospital capex environment and the pace of further bolt-on M&A, as these factors represent significant upside potential beyond current expectations.